Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cardiovascular gene therapy - Human Genome Sciences/Transgene

Drug Profile

Cardiovascular gene therapy - Human Genome Sciences/Transgene

Latest Information Update: 26 Oct 2005

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Human Genome Sciences; Transgene
  • Developer Human Genome Sciences
  • Class Gene therapies
  • Mechanism of Action Connective tissue growth factor inhibitors; Gene transference; Metalloprotease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Coronary artery restenosis; Peripheral vascular disorders

Most Recent Events

  • 26 Oct 2005 No development reported - Preclinical for Coronary artery restenosis in USA (unspecified route)
  • 26 Oct 2005 No development reported - Preclinical for Peripheral vascular disorders in USA (unspecified route)
  • 07 Mar 2002 Company deal information has been updated in the overview section of the profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top